‘Significant Discounts’ For Biosimilars Could Disrupt US Market
Pacific Research Institute Report Urges Removal Of Barriers To Price Competition
With the launch of rivals to Humira looming in 2023, removing barriers to free pricing and reforming formularies will be essential to promote biosimilar competition in the US, according to Wayne Winegarden of the Pacific Research Institute.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q3 2022
Looking back over the third quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from July to September that include changes in ownership on the horizon for major industry players, executive reshuffles at the top of leading companies and regulators, Generics Bulletin’s annual Top 50 and the announcement of our annual awards shortlist.
US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings
The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines.
AAM Laments Price Negotiation Legislation Passing US Senate
The AAM has criticized the passage of the US Inflation Reduction Act though the country’s Senate, claiming that the legislation’s “flawed framework for government price setting” will chill generic and biosimilar development and will reduce patient access.